Pelthos Therapeutics Inc. Operating Cash Flow
Pelthos Therapeutics Inc. (PTHS) reported Operating Cash Flow of -$20.79 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-13
- Pelthos Therapeutics Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$7.66M.
- Pelthos Therapeutics Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$13.13M.
- Pelthos Therapeutics Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$6.25M.
- Pelthos Therapeutics Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$15.26M.
- Pelthos Therapeutics Inc. net cash provided by (used in) operating activities for fiscal 2025 was -$22.59M.
- Pelthos Therapeutics Inc. net cash provided by (used in) operating activities for fiscal 2024 was -$5.79M.
- Pelthos Therapeutics Inc. net cash provided by (used in) operating activities for fiscal 2023 was -$981.03K.
- Pelthos Therapeutics Inc. net cash provided by (used in) operating activities for fiscal 2022 was -$1.57M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 3 month as first filed | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 6 month as first filed | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 9 month as first filed | Net Cash Provided by (Used in) Operating Activities 12 month | Net Cash Provided by (Used in) Operating Activities 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$7.66M derived: 10-Q 6 month − 10-Q/A 3 month · filed 2026-08-13 | -$20.79M 10-Q · filed 2026-08-13 | -$27.04M derived: sum of 3 quarters · filed 2026-08-13 | -$42.30M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2026-03-31 | -$13.13M 10-Q/A · filed 2026-08-13 | -$19.38M derived: sum of 2 quarters · filed 2026-08-13 | -$34.64M derived: sum of 3 quarters · filed 2026-08-13 | -$35.08M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-12-31 | -$6.25M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | -$21.51M derived: sum of 2 quarters · filed 2026-03-19 | -$21.96M derived: sum of 3 quarters · filed 2026-08-13 | -$22.59M 10-K · filed 2026-03-19 | ||||
| 2025-09-30 | -$15.26M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$15.71M derived: sum of 2 quarters · filed 2026-08-13 | -$16.34M 10-Q · filed 2025-11-13 | -$17.01M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-06-30 | -$447.00K derived: 10-Q 6 month − 10-Q/A 3 month · filed 2026-08-13 | -$1.08M 10-Q · filed 2026-08-13 | -$1.08M 10-Q · filed 2025-08-13 | -$1.75M derived: sum of 3 quarters · filed 2026-08-13 | -$1.93M derived: sum of 4 quarters · filed 2026-08-13 | |||
| 2025-03-31 | -$632.00K 10-Q/A · filed 2026-08-13 | -$632.13K 10-Q · filed 2025-05-13 | -$1.30M derived: sum of 2 quarters · filed 2026-08-13 | -$1.48M derived: sum of 3 quarters · filed 2026-08-13 | -$4.43M derived: sum of 4 quarters · filed 2026-08-13 | |||
| 2024-12-31 | -$670.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | -$847.69K derived: sum of 2 quarters · filed 2026-03-19 | -$3.80M derived: sum of 3 quarters · filed 2026-03-19 | -$5.79M 10-K · filed 2026-03-19 | -$5.79M 10-K · filed 2025-03-27 | |||
| 2024-09-30 | -$177.69K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$3.13M derived: sum of 2 quarters · filed 2025-11-13 | -$5.12M 10-Q · filed 2025-11-13 | -$5.12M 10-Q · filed 2024-11-13 | -$5.48M derived: sum of 4 quarters · filed 2025-11-13 | |||
| 2024-06-30 | -$2.95M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | -$4.94M 10-Q · filed 2025-08-13 | -$5.30M derived: sum of 3 quarters · filed 2025-08-13 | -$5.56M derived: sum of 4 quarters · filed 2025-08-13 | ||||
| 2024-03-31 | -$1.99M 10-Q · filed 2025-05-13 | -$2.35M derived: sum of 2 quarters · filed 2025-05-13 | -$2.61M derived: sum of 3 quarters · filed 2025-05-13 | -$2.80M derived: sum of 4 quarters · filed 2025-05-13 | ||||
| 2023-12-31 | -$356.81K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | -$614.04K derived: sum of 2 quarters · filed 2025-03-27 | -$807.66K derived: sum of 3 quarters · filed 2025-03-27 | -$981.03K 10-K · filed 2025-03-27 | ||||
| 2023-09-30 | -$257.24K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | -$450.86K derived: sum of 2 quarters · filed 2024-11-13 | -$624.22K 10-Q · filed 2024-11-13 | |||||
| 2023-06-30 | -$193.62K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | -$366.99K 10-Q · filed 2024-08-13 | ||||||
| 2023-03-31 | -$173.37K 10-Q · filed 2024-05-15 | |||||||
| 2022-12-31 | -$1.57M 10-K · filed 2024-04-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |